CA
NZ
UK
AU
IND
US
● The micro-cap biotech has a market value of roughly $50 million.
● AbbVie's lutikizumab showed only a modest benefit over placebo.
● The figure is a snapshot rather than a closing price.
● The figure is an intraday snapshot rather than a confirmed close.
● The company has a market value of about $21.5 million.
● The decline more than erased Wednesday's spike.
● Tyra is a clinical-stage biotech developing precision medicines.
● The premarket figure is a snapshot, not a closing price.
● The FDA lifted the clinical hold on ARD-101 for Prader-Willi syndrome.
● The biotechnology company had no company-specific news.
Please wait processing your request...